I don’t know about Ord Minnett but Morningstar has had coverage of Avita for a few years now. I don’t think they provide analyst coverage of ARX.
To compare their view on AVH v PNV, Morningstar had an estimated fair value on AVH in early 2021 of $14.30. In May 2021, Ponraj lowered the estimated fair value for AVH to $7. He was unimpressed with the company’s flat growth in procedures. He described AVH as a no-moat, single-product, single-geography company with a long road to profitability. He believed Recell had a strong position in the outpatient burns market, but noted that the product was relatively less economical.
A year later, in June 2022, he seemed to have overcome his concerns about the company, now viewing AVH as “standout’ value @ $1.72. Measured against Morningstar’s estimated fair value of $14.30 in early 2021, I guess it was!
In August this year, Morningstar quant. had a fair value for AVH of $6.46 and Morningstar Premium a fair value of $5.60. AVH is currently trading at $4.45.
- Forums
- ASX - By Stock
- PNV
- broker recommendation
broker recommendation, page-265
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PNV (ASX) to my watchlist
|
|||||
Last
$2.58 |
Change
-0.030(1.15%) |
Mkt cap ! $1.794B |
Open | High | Low | Value | Volume |
$2.61 | $2.63 | $2.57 | $893.8K | 343.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
30 | 20269 | $2.57 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.58 | 14502 | 21 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
24 | 7984 | 2.570 |
14 | 41095 | 2.560 |
17 | 97339 | 2.550 |
10 | 151536 | 2.540 |
4 | 6599 | 2.530 |
Price($) | Vol. | No. |
---|---|---|
2.580 | 11690 | 20 |
2.590 | 40316 | 26 |
2.600 | 42967 | 19 |
2.610 | 66862 | 18 |
2.620 | 207605 | 16 |
Last trade - 14.58pm 19/08/2024 (20 minute delay) ? |
Featured News
PNV (ASX) Chart |